EPS for Materialise NV (MTLS) Expected At $0.05; La Jolla Pharmaceutical Company (LJPC) Had 0 Bullish Analysts

Materialise NV (NASDAQ:MTLS) Logo

Among 2 analysts covering La Jolla Pharmaceutical (NASDAQ:LJPC), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. La Jolla Pharmaceutical had 2 analyst reports since January 14, 2019 according to SRatingsIntel. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Neutral” rating given on Wednesday, January 23 by JP Morgan. Jefferies upgraded La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Monday, January 14 to “Hold” rating. See La Jolla Pharmaceutical Company (NASDAQ:LJPC) latest ratings:

23/01/2019 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Old Target: $18 New Target: $9 Upgrade
14/01/2019 Broker: Jefferies Old Rating: Underperform New Rating: Hold Old Target: $13 New Target: $6 Upgrade

Analysts expect Materialise NV (NASDAQ:MTLS) to report $0.05 EPS on March, 5.They anticipate $0.01 EPS change or 25.00% from last quarter’s $0.04 EPS. MTLS’s profit would be $2.62M giving it 86.95 P/E if the $0.05 EPS is correct. After having $0.05 EPS previously, Materialise NV’s analysts see 0.00% EPS growth. The stock increased 2.99% or $0.51 during the last trading session, reaching $17.39. About 35,014 shares traded. Materialise NV (NASDAQ:MTLS) has risen 0.64% since February 11, 2018 and is uptrending. It has outperformed by 0.64% the S&P500. Some Historical MTLS News: 20/04/2018 – RECKITT BENCKISER GROUP PLC – “RB 2.0 IS EMBEDDING WELL” AND EXPECT TO SEE BENEFITS CONTINUE TO MATERIALISE; 06/03/2018 – Materialise 4Q EPS 4c; 06/03/2018 – Materialise 4Q Net $1.83M; 06/03/2018 MATERIALISE NV QTRLY NET PROFIT 0.03 EUR PER DILUTED SHARE; 09/05/2018 – BOJ SUMMARY: ONE IDEA COULD BE FOR BOJ, GOVT TO TAKE COORDINATED ACTION IF RISKS HAMPERING ACHIEVEMENT OF PRICE GOAL MATERIALISE; 04/05/2018 – Materialise 1Q Rev $54.1M; 06/03/2018 – Materialise to Launch TRUMATCH® Personalized Solutions Shoulder System; 06/03/2018 – Materialise 4Q Rev $53.6M; 04/05/2018 – Materialise 1Q EPS $0.00; 13/03/2018 – OMV CEO SAYS WOULD NOT REWRITE STRATEGY IF NORDSTREAM 2 DIDN’T MATERIALISE

More notable recent Materialise NV (NASDAQ:MTLS) news were published by: Nasdaq.com which released: “European ADRs Move Lower in Friday Trading – Nasdaq” on February 01, 2019, also Nasdaq.com with their article: “European ADRs Move Higher in Tuesday Trading – Nasdaq” published on January 29, 2019, Nasdaq.com published: “Best 3D Printing Stocks Set to Gain in 2019 – Nasdaq” on January 24, 2019. More interesting news about Materialise NV (NASDAQ:MTLS) were released by: Fool.com and their article: “Stratasys and 3D Systems Stocks Upgraded: Is a 3D Printing Rebound Coming? – The Motley Fool” published on January 29, 2019 as well as Bizjournals.com‘s news article titled: “With fresh $22M in bank, 3D-printing startup moving to Austin area – Austin Business Journal” with publication date: January 25, 2019.

Materialise NV provides additive manufacturing software and 3D printing services in Europe, the Americas, and Asia. The company has market cap of $910.67 million. The company's Materialise Software segment offers proprietary software worldwide through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. It has a 179.23 P/E ratio. The Company’s software interfaces between various types of 3D printers, and various software applications and capturing technologies, including computer-aided design packages and 3D scanners.

Since August 16, 2018, it had 7 buys, and 1 sale for $4.62 million activity. 1,000 shares valued at $20,895 were bought by CARVER JENNIFER on Thursday, August 16. Rolke James had bought 1,000 shares worth $21,997. 2,000 La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares with value of $11,700 were bought by TIDMARSH GEORGE F. 3,000 shares were bought by Chawla Lakhmir S, worth $16,694. $6.99M worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) was bought by TANG KEVIN C on Monday, January 7. 2.06M shares were sold by PERCEPTIVE ADVISORS LLC, worth $11.72 million.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $153.60 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

More notable recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” on February 05, 2019, also Streetinsider.com with their article: “SunTrust Robinson Humphrey Assumes La Jolla Pharma (LJPC) at Buy – StreetInsider.com” published on January 17, 2019, Seekingalpha.com published: “UBS likes Lilly in premarket analyst action – Seeking Alpha” on January 23, 2019. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) were released by: Globenewswire.com and their article: “La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference – GlobeNewswire” published on January 04, 2019 as well as Benzinga.com‘s news article titled: “10 Biggest Price Target Changes For Monday – Benzinga” with publication date: January 14, 2019.

Investors sentiment decreased to 1.23 in Q3 2018. Its down 0.27, from 1.5 in 2018Q2. It worsened, as 15 investors sold La Jolla Pharmaceutical Company shares while 16 reduced holdings. 10 funds opened positions while 28 raised stakes. 32.70 million shares or 8.66% more from 30.09 million shares in 2018Q2 were reported. Alliancebernstein Ltd Partnership reported 0% stake. Dimensional Fund Advsr Lp holds 0% or 35,137 shares. Deutsche Savings Bank Ag holds 42,944 shares or 0% of its portfolio. Cubist Systematic Strategies Ltd Liability holds 49 shares or 0% of its portfolio. State Of Wisconsin Board invested 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Vanguard Group Incorporated has invested 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Ubs Asset Americas Inc invested in 11,200 shares. Commercial Bank Of Ny Mellon owns 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 90,949 shares. Northern Tru owns 304,226 shares for 0% of their portfolio. 38,008 were accumulated by First Midwest National Bank Trust Division. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). California Pub Employees Retirement owns 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 31,900 shares. Bnp Paribas Arbitrage Sa reported 730 shares or 0% of all its holdings. 117,476 were reported by Emory University. New York State Common Retirement Fund stated it has 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC).

The stock increased 3.26% or $0.18 during the last trading session, reaching $5.86. About 148,756 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 56.94% since February 11, 2018 and is downtrending. It has underperformed by 56.94% the S&P500. Some Historical LJPC News: 16/05/2018 – California’s First Accredited Geriatric Emergency Department Arrives in La Jolla; 15/03/2018 – La Jolla Pharmaceutical: Proceeds From Offering About $100.3 Million; 22/05/2018 – SERITAGE GROWTH PROPERTIES – CO, INVESCO REAL ESTATE ANNOUNCE PARTNERSHIP TO OWN COLLECTION AT UTC IN LA JOLLA, CALIFORNIA; 15/03/2018 – RCUS, HGV to Trade, ZS, LJPC to Price: Equity Capital Markets; 15/05/2018 – Scopia Capital Management Buys 2.2% Position in La Jolla Pharma; 22/03/2018 – La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin Il) in the United States; 22/03/2018 – La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States; 06/03/2018 – LA JOLLA REPORTS DATA ON GIAPREZA FOR ACUTE KIDNEY INJURY; 10/05/2018 – LA JOLLA PHARMACEUTICAL CO LJPC.O QUARTERLY SHR LOSS $2.22; 05/03/2018 Pure Spectrum CBD Retail Store Opens in La Jolla, California

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.